Compile Data Set for Download or QSAR
maximum 50k data
Found 24 Enz. Inhib. hit(s) with Target = 'Tyrosine-protein kinase BTK' and Ligand = 'BDBM230107'
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)
Affinity DataIC50:  0.260nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)
Affinity DataIC50:  0.260nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)
Affinity DataIC50:  0.260nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)
Affinity DataIC50:  0.330nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)
Affinity DataIC50:  0.480nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)
Affinity DataIC50:  0.550nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)
Affinity DataIC50:  0.550nMAssay Description:Inhibition of recombinant full-length His-tagged human BTK expressed in baculovirus expression system using fluoresceinated peptide as substrate incu...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)
Affinity DataIC50:  0.550nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)
Affinity DataIC50:  0.550nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)
Affinity DataIC50:  0.550nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)
Affinity DataIC50:  1nMAssay Description:Inhibition of BTK in human peripheral B cells assessed as reduction in anti-IgM/IgG-induced CD86 surface expressionMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)
Affinity DataIC50:  2nMAssay Description:Inhibition of BTK in human PBMC cells assessed as inhibition of FCepsilonR1/immune complex-induced TNFalpha productionMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)
Affinity DataIC50:  10nMAssay Description:Inhibition of BTK in human Ramos B cells assessed as reduction in goat anti human IgM-stimulated calcium flux preincubated for 1 hr followed by goat ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)
Affinity DataIC50:  10nMAssay Description:Inhibition of BTK in human Ramos B cells assessed as reduction in goat anti human IgM-stimulated calcium flux preincubated for 1 hr followed by goat ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)
Affinity DataIC50:  17nMAssay Description:Inhibition of recombinant full-length His-tagged human BTK expressed in baculovirus expression system using fluoresceinated peptide as substrate incu...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)
Affinity DataIC50:  54nMAssay Description:Inhibition of BTK in human whole blood assessed as reduction in FCepsilonR1/anti-IgE-induced CD63 surface expression on basophilsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)
Affinity DataIC50:  87nMAssay Description:Inhibition of BTK in human Ramos B cells assessed as reduction in goat anti human IgM-stimulated calcium flux preincubated for 1 hr followed by goat ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Mus musculus)
Bristol Myers Squibb Research

Curated by ChEMBL
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)
Affinity DataIC50:  130nMAssay Description:Inhibition of BTK in mouse whole blood assessed as reduction in anti-IgM/IgG-induced CD69 surface expression on peripheral B cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)
Affinity DataIC50:  162nMAssay Description:Inhibition of BTK in human whole blood assessed as reduction in goat anti human IgM/human IL4-stimulated CD69 cell surface expression on peripheral B...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)
Affinity DataIC50:  162nMAssay Description:Inhibition of BTK in human whole blood assessed as reduction in goat anti human IgM/human IL4-stimulated CD69 cell surface expression on peripheral B...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)
Affinity DataIC50:  180nMAssay Description:Inhibition of recombinant full-length His-tagged human BTK expressed in baculovirus expression system using fluoresceinated peptide as substrate incu...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)
Affinity DataIC50:  180nMAssay Description:Inhibition of recombinant full-length His-tagged human BTK expressed in baculovirus expression system using fluoresceinated peptide as substrate incu...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)
Affinity DataIC50: >300nMAssay Description:Inhibition of BTK in human Ramos B cells assessed as reduction in goat anti human IgM-stimulated calcium flux preincubated for 1 hr followed by goat ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230107(US10106559, Example 33 | US10435415, Example 33 | ...)
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of BTK in human peripheral B cells assessed as reduction in CD40/CD40L-induced CD86 surface expressionMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed